BioSpace News Archive

SpecialtyCare’s real-time cohort of 32 patients across 9 states over 24 days is the largest published analysis to date of COVID-19 patients supported with ECMO. SpecialtyCare pledges to continue research and hopes to partner with other industry leaders to support providers as the COVID-19 pandemic evolves

CVS Health Corporation will hold a conference call with analysts and investors on Wednesday, May 6, 2020, at 8:00 a.m. to discuss its financial results for the first quarter of 2020..

Today, the U.S. Food and Drug Administration issued a letter to Bayer outlining conditions for submitting additional postmarket information to the agency about Essure—a permanent birth control device Bayer sold in the U.S. until 2018. The letter applies to reportable adverse events Bayer is or becomes aware of from social medi

Company’s subsidiary ViralClear recently submitted an Investigational New Drug application to the FDA for its Phase II clinical trial with Merimepodib as a treatment for COVID-19

A large number of humanized liver mice models are available, including uPA-SCID mice, FRG KO mice, and TK-NOG mice, among others. Factors such as increasing incidence of liver cirrhosis, technological advancement and development of new humanized liver mice models, increase in number of FDA approvals for liver-based disease treatment dugs have increased the number of research and development activities, which require these models.

Plasma protein therapeutics industry leading efforts to fight COVID-19